CN105755108A - 烟曲霉实时pcr技术 - Google Patents
烟曲霉实时pcr技术 Download PDFInfo
- Publication number
- CN105755108A CN105755108A CN201510586315.3A CN201510586315A CN105755108A CN 105755108 A CN105755108 A CN 105755108A CN 201510586315 A CN201510586315 A CN 201510586315A CN 105755108 A CN105755108 A CN 105755108A
- Authority
- CN
- China
- Prior art keywords
- copies
- aspergillus fumigatus
- detection
- pcr
- sensitivity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241001225321 Aspergillus fumigatus Species 0.000 title claims abstract description 8
- 229940091771 aspergillus fumigatus Drugs 0.000 title claims abstract description 7
- 238000003753 real-time PCR Methods 0.000 title claims abstract description 6
- 238000001514 detection method Methods 0.000 claims abstract description 16
- 239000000523 sample Substances 0.000 claims abstract description 8
- 241001003127 Tarma Species 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 8
- 230000035945 sensitivity Effects 0.000 abstract description 6
- 208000031888 Mycoses Diseases 0.000 abstract description 5
- 210000000056 organ Anatomy 0.000 abstract description 3
- 238000002054 transplantation Methods 0.000 abstract description 3
- 238000010322 bone marrow transplantation Methods 0.000 abstract description 2
- 238000002512 chemotherapy Methods 0.000 abstract description 2
- 208000030507 AIDS Diseases 0.000 abstract 1
- 238000011895 specific detection Methods 0.000 abstract 1
- 201000007946 Congenital intrinsic factor deficiency Diseases 0.000 description 6
- 208000034419 hereditary intrinsic factor deficiency Diseases 0.000 description 6
- 238000013399 early diagnosis Methods 0.000 description 5
- 241000233866 Fungi Species 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 3
- 206010011409 Cross infection Diseases 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 208000037026 Invasive Fungal Infections Diseases 0.000 description 2
- 206010029803 Nosocomial infection Diseases 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241001136487 Eurotium Species 0.000 description 1
- 229920000926 Galactomannan Polymers 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 241000228404 Histoplasma capsulatum Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 241001149962 Sporothrix Species 0.000 description 1
- 206010042566 Superinfection Diseases 0.000 description 1
- 241000202921 Ureaplasma urealyticum Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000013211 curve analysis Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003771 laboratory diagnosis Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000012772 sequence design Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/6895—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Analytical Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
近20多年来,由于艾滋病患者的增多,新的治疗技术和骨髓移植、器官移植和强化化疗等广泛应用于临床,侵袭性真菌病的发病率明显升高,严重危害人类健康,甚至危及生命,大大增加了临床治疗的难度,已引起广泛高度重视,本实验室建立了一种针对烟曲霉进行特异性检测的荧光定量PCR方法(探针法),该PCR检测体系的检测敏感性方面,线性检测范围的下限可至102copies/ml,上限可达108copies/ml,敏感性、特异性和稳定性均较好。
Description
本申请是分案申请,母案的申请日为2013年8月15日,申请号为201310355569.5,发明名称是烟曲霉实时PCR技术。
技术领域
近20年多年来,由于艾滋病患者的增多,新的治疗技术和骨髓移植、器官移植和强化化疗等广泛应于临床,侵入性检测设备,胃肠外营养,光谱抗生素的长期应用以及危重患者辅助机械通气代替治疗、老龄人口的增多等原因,侵袭性真菌病的发病率明显升高,特别是一些免疫功能低下患者如恶性肿瘤病人继发感染以及器官移植失败等医院内感染问题常常由真菌感染所致,严重危害人类健康,甚至危及生命,大大增加了临床治疗的难度,已引起广泛高度重视,Chandrasekar等人报道了造血干细胞移植的患者移植后出现侵袭性真菌病的患病率大于30%,而移植后因感染IFD而死亡的比率高达70%-90%,IFD的早发现早治疗对于改善患者预后具有重要意义,而当前实验室内的常规检测方法由于其敏感性和耗时性等缺陷,难以满足临床的需求,亟需寻求一种更加灵敏和特异的检测方法,为目前临床真菌感染的早期诊断、预防和治疗提供有效工具。随着近年来对真菌病原研究的不断深入,使人们重新看到了真菌PCR在临床应用的曙光,本课题组大胆求索,建立了一种针对烟曲霉病原菌进行检测的实时PCR法。
背景技术
侵袭性真菌感染(IFD)十分普遍,主要由念珠球菌属、曲霉属、隐球菌属等机会致病真菌(或条件致病真菌)引起,也可由组织胞浆菌、皮炎牙生菌、孢子丝菌等地方流行性致病真菌所致,其中曲霉菌属已成为免疫低下患者二次感染的重要致命因素,IFD的早期诊断和早期治疗对于改善病人预后有着重要意义,而当前真菌感染的特点是高院内感染率、低实验室诊断率、低临床诊断率和病情进展迅速,传统诊断方法包括深部组织培养法、组织/细胞病理学检测、1-3-β-D葡聚糖(G试验)、半乳甘露聚糖检测(GM试验)和影像学检查(如CT)等,由于它们在敏感性、特异性等方面存在缺陷,难以满足临床早期诊断的需要,如何提高IFD的早期诊断、早期治疗是国内外学者关注的热点问题,所以近年来IFD的早期诊断方法的研究被广泛开展,虽然当前仍处于实验室研究阶段,但其应用前景广阔,值得期待。
发明内容
将烟曲霉线粒体基因组大小为30696bp,将其基因组序列在http://blast.ncbi.nlm.nih.gov/Blast.cgi数据库中进行比对,找到特有的靶序列部分,在靶序列上设计一对,上游引物:5'-CTTGAATACTTCAGTAACT-3',下游引物5'-CCTCTATTTACTAAATCATC-3';探针5'FAM-GCAAGGCGATTTATCTCACCACT-3'TARMA,靶片段长度132bp。具体靶序列cttgaatacttcagtaactattagtaatatgttattagattctgatatatatcataatcatatagatagaagaataataatgatacaaagtggtgagataaatcgccttgctgatgatttagtaaatagagg(132bp)。
构建含靶片段的TA克隆质粒(委托宝生物公司完成),制备梯度浓度的双份样本,具体浓度为101copies/ml、102copies/ml、103copies/ml、104copies/ml、105copies/ml、106copies/ml、107copies/ml、108copies/ml,进行PCR扩增并作融解曲线分析,验证该方法的敏感性、稳定性与特异性,同时分别以非烟曲霉菌基因组DNA,即白色念珠菌标准株(ATCC90028)基因组DNA、解脲支原体基因组DNA、人基因组DNA、人巨细胞病毒(HCMV)基因组DNA和HBV基因组DNA为模板,进一步验证该方法的特异性;将PCR产物外送检测,验证方法的可靠性。
PCR反应总体积为50μL,包括10×缓冲液(20MmMg2+plus)5μL,TaKaRaExTaqDNA聚合酶(5U/μL)0.8μL,dNTPs(各2.5mmol/L)4μL,上游引物(10μmol/L)3μL,下游引物(10μmol/L)3μL,探针(10μmol/L)3μL,DNA模板1μL,加高压灭菌后的双蒸水(ddH2O)将反应体积补足至50μL。PCR体系反应条件为:94℃预变性3min;94℃变性10s,55℃退火延伸40s,共40个循环。
PCR扩增标准曲线的斜率-3.014383,截距40.882465,相关系数R2:0.997539,提示具有较好的相关性,(说明书附图1)。该PCR检测体系的检测敏感性方面,线性检测范围的下限可至102copies/ml,上限可达108copies/ml;双份样本的检测结果总体一致(说明书附图2),提示该PCR检测体系的重复性、稳定性较好,PCR产物外送测序,测序结果符合预期。
附图说明:图1为PCR扩增标准曲线图;图2为PCR扩增曲线。
Claims (1)
1.一种用于烟曲霉实时PCR检测的探针,其特征在于,所述探针为5'FAM-GCAAGGCGATTTATCTCACCACT-3'TARMA;所述探针的设计是针对如下靶序列:cttgaatacttcagtaactattagtaatatgttattagattctgatatatatcataatcatatagatagaagaataataatgatacaaagtggtgagataaatcgccttgctgatgatttagtaaatagagg。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510586315.3A CN105755108B (zh) | 2013-08-15 | 2013-08-15 | 烟曲霉实时pcr技术 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510586315.3A CN105755108B (zh) | 2013-08-15 | 2013-08-15 | 烟曲霉实时pcr技术 |
CN201310355569.5A CN103773838B (zh) | 2013-08-15 | 2013-08-15 | 烟曲霉实时pcr技术 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310355569.5A Division CN103773838B (zh) | 2013-08-15 | 2013-08-15 | 烟曲霉实时pcr技术 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105755108A true CN105755108A (zh) | 2016-07-13 |
CN105755108B CN105755108B (zh) | 2019-01-08 |
Family
ID=56341884
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510586315.3A Expired - Fee Related CN105755108B (zh) | 2013-08-15 | 2013-08-15 | 烟曲霉实时pcr技术 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105755108B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102041306A (zh) * | 2010-08-18 | 2011-05-04 | 李国辉 | 一种检测烟曲霉的dna探针、基因芯片及其应用 |
CN102311994A (zh) * | 2011-04-19 | 2012-01-11 | 山东农业大学 | 烟曲霉荧光定量pcr检测方法 |
-
2013
- 2013-08-15 CN CN201510586315.3A patent/CN105755108B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102041306A (zh) * | 2010-08-18 | 2011-05-04 | 李国辉 | 一种检测烟曲霉的dna探针、基因芯片及其应用 |
CN102311994A (zh) * | 2011-04-19 | 2012-01-11 | 山东农业大学 | 烟曲霉荧光定量pcr检测方法 |
Non-Patent Citations (1)
Title |
---|
ANA ABAD-DIAZ-DE-CERIO等: "The aspHS gene as a new target for detecting Aspergillus fumigatus during infections by quantitative real-time PCR", 《MEDICAL MYCOLOGY》 * |
Also Published As
Publication number | Publication date |
---|---|
CN105755108B (zh) | 2019-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111690760A (zh) | 一种准确检测新生隐球菌的方法 | |
CN104630353A (zh) | 一种用于鼻咽癌诊断、预后判断、治疗效果评估的试剂盒 | |
CN111808963A (zh) | 一种用于早期肺癌无创筛查的组合物、应用与试剂盒及样本处理方法 | |
CN104263842B (zh) | 一种鱼源无乳链球菌的荧光定量pcr检测方法 | |
Shokohi et al. | Candida infanticola and Candida spencermartinsiae yeasts: Possible emerging species in cancer patients | |
CN102634605B (zh) | 检测鸡产蛋下降综合征病毒的方法及其试剂盒 | |
CN102952850B (zh) | 用于检测结核分枝杆菌的实时荧光定量pcr方法、引物、探针及试剂盒 | |
CN110093432A (zh) | 一种用于区分结核杆菌和BCG疫苗的sRNA标志物及其用途 | |
CN104004837B (zh) | 检测结核分枝杆菌的pcr引物、引物组、探针及其试剂盒和检测方法 | |
CN106967792B (zh) | Dkk-3基因甲基化诊断试剂体系、试剂盒及其应用 | |
Tabone et al. | Prevalence of human papillomavirus genotypes in women with cervical cancer in Papua New Guinea | |
CN108060231A (zh) | 用于宫颈癌基因FAM19A4、miR-124-2甲基化检测的引物对、试剂盒及方法 | |
CN103773838B (zh) | 烟曲霉实时pcr技术 | |
CN107419008A (zh) | 一种早期精确诊断帕金森病的方法和试剂盒 | |
CN111424101A (zh) | 一种用于定量检测耶氏肺孢子菌的试剂盒和方法 | |
Wilmes et al. | Disseminated coccidioidomycosis: Monitoring of serologic markers for treatment response | |
WO2020134950A1 (zh) | 用于肺结节良恶性鉴别的基因突变/融合组合及试剂盒 | |
CN102676697A (zh) | 检测小反刍兽疫病毒的引物和探针及试剂盒 | |
CN105755108A (zh) | 烟曲霉实时pcr技术 | |
CN109182524A (zh) | 一种辅助诊断宫颈癌及其癌前病变的miRNA组合标志物及其应用 | |
CN107299144A (zh) | 一种用于检测TNF‑a基因SNP位点rs1799724基因型的扩增引物、试剂盒、方法及其应用 | |
CN112501280B (zh) | 一种基于高通量测序的泡型包虫高灵敏度检测方法 | |
CN104087671A (zh) | 一种用于检测人21号染色体数目的试剂盒 | |
CN104651492A (zh) | miRNA410-在制备前列腺癌诊断试剂盒中的应用 | |
CN107858425A (zh) | miRNA‑4741作为原发性肝癌诊断标志物的应用及检测方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20191204 Address after: 201900 Shanghai city Baoshan District Luxiang Road No. 108 Patentee after: North Hospital of Huashan Hospital Affiliated to Fudan University Address before: 201108 Shanghai city Minhang District Yindu road 3151 Lane 7, room 701 Co-patentee before: Xing Zhifang Patentee before: Cao Guojun |
|
TR01 | Transfer of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20190108 Termination date: 20200815 |
|
CF01 | Termination of patent right due to non-payment of annual fee |